Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Athira Pharma, Inc. - Common Stock (NQ:ATHA)

0.2702 -0.0003 (-0.11%)
Streaming Delayed Price Updated: 10:54 AM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,586
Open 0.2635
Bid (Size) 0.2702 (4)
Ask (Size) 0.2720 (11)
Prev. Close 0.2705
Today's Range 0.2635 - 0.2720
52wk Range 0.2195 - 3.670
Shares Outstanding 38,054,583
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire

Performance

YTD
-50.9%
-50.9%
1 Month
+0.4%
+0.4%
3 Month
-39.8%
-39.8%
6 Month
-59.0%
-59.0%
1 Year
-89.7%
-89.7%

More News

Read More
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
From Athira Pharma, Inc.
Via GlobeNewswire
Robinhood To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
From Athira Pharma, Inc.
Via GlobeNewswire
Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings
Via Benzinga
Exposures Fossil Fuels
US Stocks Mixed; Trade Gap Widens In July
Via Benzinga
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
Via Benzinga
Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
From Athira Pharma, Inc.
Via GlobeNewswire
ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024
Via InvestorPlace
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
From Athira Pharma, Inc.
Via GlobeNewswire
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma to Participate in Upcoming June Conferences
From Athira Pharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Athira Pharma, Inc. - Common Stock publicly traded?
Yes, Athira Pharma, Inc. - Common Stock is publicly traded.
What exchange does Athira Pharma, Inc. - Common Stock trade on?
Athira Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Athira Pharma, Inc. - Common Stock?
The ticker symbol for Athira Pharma, Inc. - Common Stock is ATHA on the Nasdaq Stock Market
What is the current price of Athira Pharma, Inc. - Common Stock?
The current price of Athira Pharma, Inc. - Common Stock is 0.2702
When was Athira Pharma, Inc. - Common Stock last traded?
The last trade of Athira Pharma, Inc. - Common Stock was at 05/23/25 10:54 AM ET
What is the market capitalization of Athira Pharma, Inc. - Common Stock?
The market capitalization of Athira Pharma, Inc. - Common Stock is 10.28M
How many shares of Athira Pharma, Inc. - Common Stock are outstanding?
Athira Pharma, Inc. - Common Stock has 10M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.